Cancer drug shows promise in limiting COVID-19 inflammation

📆 9/18/2023 7:14 PM
📰 medical_xpress

⏱ Reading Time:
8 sec. here
2 min. at publisher
📊 Quality Score:
News: 7%
Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A cancer drug could play an important role in limiting the damaging effects of lung disease in COVID-19 patients, thanks to new research at Hudson Institute of Medical Research.

Now a team led by Associate Professor Michael Gantier has established that idronoxil, which was originally designed to treat cancers, could reduce the inflammation that occurs in response to COVID-19."Early in the COVID-19 pandemic we realized that uncontrolled inflammation was one of the major life-threatening aspects of the infection, but we didn't know exactly how this inflammation occurred," Gantier said.

"In other words, we can let the body's inflammatory response go to work without going too far—we've restored the off-switch."

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

'We need to normalise conversations about cancer and life after cancer'Mum-of-three Tracey is on a mission to help improve conversations about cancer after being treated for womb cancer
Source: MENnewsdesk - 🏆 23. / 69 Read more »